Subtopic Deep Dive
Breast Cancer Comprehensive Genomic Profiling
Research Guide
What is Breast Cancer Comprehensive Genomic Profiling?
Breast Cancer Comprehensive Genomic Profiling integrates multi-omics data from TCGA to characterize PAM50 subtypes, ESR1/HER2 mutations, and homologous recombination deficiency signatures for precision diagnostics.
TCGA analyses of primary breast cancers used genomic DNA copy number arrays, DNA methylation, exome sequencing, mRNA arrays, microRNA sequencing, and protein arrays (Koboldt et al., 2012; 12,031 citations). Studies refine somatic mutation profiles across 2,433 breast cancers to define genomic and transcriptomic landscapes (Pereira et al., 2016; 1,745 citations). Over 20 TCGA marker papers across 33 tumor types enable integrative analysis via tools like TCGAbiolinks (Colaprico et al., 2015; 4,233 citations).
Why It Matters
PAM50 subtyping from TCGA data stratifies breast cancer patients for targeted therapies, improving survival by matching ESR1/HER2 mutations to endocrine and HER2 inhibitors (Koboldt et al., 2012). Homologous recombination deficiency signatures identify PARP inhibitor candidates, expanding treatment options (Ciriello et al., 2013). Tumor purity estimation refines genomic signals perturbed by stromal/immune admixture, enhancing immunotherapy response predictions (Yoshihara et al., 2013). Maftools enables efficient somatic variant analysis for clinical trial design (Mayakonda et al., 2018).
Key Research Challenges
Tumor Purity Estimation
Stromal and immune cell admixture perturbs tumor genomic signals in expression data (Yoshihara et al., 2013; 10,335 citations). ESTIMATE algorithm infers purity but requires validation across breast cancer subtypes. Integrating purity corrections with PAM50 subtyping remains inconsistent.
Multi-Omics Integration
TCGA breast cancer data spans copy number, methylation, exome, and transcriptomics, demanding unified analysis (Koboldt et al., 2012; 12,031 citations). TCGAbiolinks facilitates access but harmonization across platforms challenges subtype-specific insights (Colaprico et al., 2015). Computational scalability limits pan-cancer scaling.
Somatic Variant Prioritization
2,433 breast cancers reveal complex mutational landscapes needing significance scoring (Pereira et al., 2016; 1,745 citations). Maftools provides analysis but distinguishing drivers from passengers in ESR1/HER2 contexts requires advanced statistics (Mayakonda et al., 2018).
Essential Papers
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt · 2012 · Nature · 12.0K citations
We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our ability to i...
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez et al. · 2013 · Nature Communications · 10.3K citations
Infiltrating stromal and immune cells form the major fraction of normal cells in tumour tissue and not only perturb the tumour signal in molecular studies but also have an important role in cancer ...
Integrated genomic characterization of endometrial carcinoma
Gad Getz · 2013 · Nature · 5.6K citations
We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine serous tumours and ∼25% of hi...
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Anand Mayakonda, De‐Chen Lin, Yassen Assenov et al. · 2018 · Genome Research · 5.2K citations
Numerous large-scale genomic studies of matched tumor-normal samples have established the somatic landscapes of most cancer types. However, the downstream analysis of data from somatic mutations en...
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth, Michael D. McLellan, Fabio Vandin et al. · 2013 · Nature · 4.4K citations
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
Antonio Colaprico, Tiago C. Silva, Catharina Olsen et al. · 2015 · Nucleic Acids Research · 4.2K citations
The Cancer Genome Atlas (TCGA) research network has made public a large collection of clinical and molecular phenotypes of more than 10 000 tumor patients across 33 different tumor types. Using thi...
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Jianfang Liu, Tara M. Lichtenberg, Katherine A. Hoadley et al. · 2018 · Cell · 3.7K citations
Reading Guide
Foundational Papers
Start with Koboldt et al. (2012) for TCGA breast multi-omics baseline (12,031 citations); Yoshihara et al. (2013) for purity estimation essential to all downstream analyses (10,335 citations).
Recent Advances
Pereira et al. (2016) refines mutation landscapes (1,745 citations); Mayakonda et al. (2018) maftools for variant analysis (5,162 citations).
Core Methods
ESTIMATE (Yoshihara 2013); TCGAbiolinks (Colaprico 2015); maftools (Mayakonda 2018) for purity, data access, and variant prioritization.
How PapersFlow Helps You Research Breast Cancer Comprehensive Genomic Profiling
Discover & Search
Research Agent uses searchPapers and citationGraph to map TCGA breast cancer literature from Koboldt et al. (2012), revealing 12,031 downstream citations including Pereira et al. (2016). exaSearch uncovers PAM50-specific papers; findSimilarPapers extends to ESR1 mutation studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract TCGA multi-omics protocols from Koboldt et al. (2012), then runPythonAnalysis with maftools (Mayakonda et al., 2018) for somatic variant stats. verifyResponse via CoVe chain-of-verification flags purity estimation errors (Yoshihara et al., 2013); GRADE scores evidence for HRD signatures.
Synthesize & Write
Synthesis Agent detects gaps in ESR1/HER2 immunotherapy correlations across TCGA papers. Writing Agent uses latexEditText for PAM50 subtype tables, latexSyncCitations for 20+ TCGA references, and latexCompile for publication-ready reviews; exportMermaid diagrams oncogenic pathways from Ciriello et al. (2013).
Use Cases
"Run TCGA breast cancer purity analysis on PAM50 subtypes"
Research Agent → searchPapers('Yoshihara ESTIMATE TCGA breast') → Analysis Agent → runPythonAnalysis(ESTIMATE on TCGAbiolinks data) → purity scores and subtype correlations output as CSV.
"Write LaTeX review of ESR1 mutations in breast cancer genomics"
Synthesis Agent → gap detection(ESR1 across Koboldt/Pereira) → Writing Agent → latexEditText(draft) → latexSyncCitations(TCGA papers) → latexCompile → compiled PDF with figures.
"Find GitHub code for maftools breast cancer analysis"
Research Agent → searchPapers('Maftools Mayakonda') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → R scripts for somatic variants with usage examples.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TCGA breast papers: searchPapers → citationGraph → readPaperContent → GRADE grading → structured report on PAM50 evolution. DeepScan applies 7-step analysis with CoVe checkpoints to verify HRD signatures in Pereira et al. (2016). Theorizer generates hypotheses linking Yoshihara purity (2013) to immunotherapy from pan-cancer data.
Frequently Asked Questions
What is Breast Cancer Comprehensive Genomic Profiling?
Integration of TCGA multi-omics data to define PAM50 subtypes, ESR1/HER2 mutations, and HRD signatures (Koboldt et al., 2012).
What methods analyze TCGA breast cancer data?
TCGAbiolinks for data access (Colaprico et al., 2015); maftools for somatic variants (Mayakonda et al., 2018); ESTIMATE for tumor purity (Yoshihara et al., 2013).
What are key papers?
Koboldt et al. (2012; 12,031 citations) for multi-omics portraits; Pereira et al. (2016; 1,745 citations) for 2,433 breast cancer mutations.
What open problems exist?
Scalable multi-omics integration for subtype-specific drivers; validating HRD signatures for immunotherapy beyond TCGA cohorts.
Research Cancer Genomics and Diagnostics with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Breast Cancer Comprehensive Genomic Profiling with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Cancer Genomics and Diagnostics Research Guide